Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
86M
-
Number of holders
-
472
-
Total 13F shares, excl. options
-
56.7M
-
Shares change
-
+1.94M
-
Total reported value, excl. options
-
$3.86B
-
Value change
-
+$140M
-
Put/Call ratio
-
0.85
-
Number of buys
-
218
-
Number of sells
-
-189
-
Price
-
$68.16
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q1 2024
576 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q1 2024.
CRISPR Therapeutics AG - Common Stock (CRSP) has 472 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56.7M shares
of 86M outstanding shares and own 65.94% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (8.16M shares), Capital International Investors (7.84M shares), Nikko Asset Management Americas, Inc. (3.27M shares), Sumitomo Mitsui Trust Holdings, Inc. (3.27M shares), T. Rowe Price Investment Management, Inc. (2.7M shares), BlackRock Inc. (2.55M shares), FMR LLC (2.24M shares), VANGUARD GROUP INC (1.64M shares), STATE STREET CORP (1.5M shares), and EcoR1 Capital, LLC (1.39M shares).
This table shows the top 472 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.